Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
EZH2 Y641F EPZ005687 lymphoma sensitive detail...
EZH2 Y646F Tazemetostat lymphoma sensitive detail...
Unknown unknown Metformin + Aldoxorubicin lymphoma not applicable detail...
Unknown unknown Birinapant lymphoma not applicable detail...
AKT1 act mut Doxorubicin lymphoma decreased response detail...
AKT1 act mut Sirolimus lymphoma no benefit detail...
AKT1 act mut Doxorubicin + Sirolimus lymphoma predicted - sensitive detail...
Unknown unknown Everolimus lymphoma not applicable detail...
Unknown unknown Copanlisib lymphoma not applicable detail...
Unknown unknown Ixazomib lymphoma not applicable detail...
Unknown unknown Ixazomib + JQ1 lymphoma not applicable detail...
NRAS mutant Trametinib lymphoma sensitive detail...
Unknown unknown CPI-0610 lymphoma not applicable detail...
Unknown unknown Marizomib lymphoma not applicable detail...
Unknown unknown S63845 lymphoma not applicable detail...
Unknown unknown PU-H71 lymphoma not applicable detail...
Unknown unknown Denileukin diftitox + Sirolimus lymphoma not applicable detail...
Unknown unknown Abexinostat lymphoma not applicable detail...
Unknown unknown ACP-319 lymphoma not applicable detail...
TP53 wild-type ALRN-6924 lymphoma predicted - sensitive detail...
Unknown unknown Bendamustine + Veliparib lymphoma not applicable detail...
Unknown unknown Carfilzomib + EDO-S101 lymphoma not applicable detail...
Unknown unknown Bortezomib + Tinostamustine lymphoma not applicable detail...
Unknown unknown GNE-272 lymphoma not applicable detail...
ALK negative CEP-28122 lymphoma resistant detail...
Unknown unknown PQR309 lymphoma not applicable detail...
Unknown unknown PQR309 + Venetoclax lymphoma not applicable detail...
Unknown unknown Panobinostat + PQR309 lymphoma not applicable detail...
Unknown unknown PQR309 + Rituximab lymphoma not applicable detail...
Unknown unknown APTO-253 lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT00368082 Phase I Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta) Active, not recruiting
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Recruiting
NCT00918333 Phase Ib/II Panobinostat + Everolimus Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Active, not recruiting
NCT01237236 Phase I Ribociclib A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. Completed
NCT01273155 Phase I Belinostat Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction Completed
NCT01287546 Phase I Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab A Study of LY2875358 in Participants With Advanced Cancer Completed
NCT01326702 Phase Ib/II Veliparib Rituximab Bendamustine Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Active, not recruiting
NCT01363817 Phase I Dexamethasone BMS-906024 Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed
NCT01393509 Phase I PU-H71 The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies Active, not recruiting
NCT01473095 Phase I ARQ092 Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Completed
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Active, not recruiting
NCT01564251 Phase I GDC-0575 + Gemcitabine GDC-0575 A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma Completed
NCT01576406 Phase I Crizotinib Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients Completed
NCT01596270 Phase I SAR245409 A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma Completed
NCT01625351 Phase I Fludarabine Melphalan Busulfan Alemtuzumab A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting
NCT01636479 Phase I SAR405838 Phase 1 Safety Testing of SAR405838 Completed
NCT01638533 Phase I romidepsin Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Recruiting
NCT01655225 Phase I LY3023414 + Midazolam LY3023414 + Letrozole LY3023414 A Study of LY3023414 in Participants With Advanced Cancer Recruiting
NCT01665768 Phase II Rituximab Everolimus Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Active, not recruiting
NCT01670175 Phase I Sirolimus + Cyclophosphamide + Topotecan Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors Completed
NCT01673737 Phase I SAR260301 SAR260301 + Vemurafenib A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer Completed
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01703481 Phase I Erdafitinib A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma Completed
NCT01703572 Phase I Brontictuzumab A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Completed
NCT01703949 Phase II Brentuximab vedotin Brentuximab vedotin + Nivolumab Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma Recruiting
NCT01742988 Phase I CUDC-907 Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma Active, not recruiting
NCT01744223 Phase Ib/II Rimiducid BPX-501 Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated
NCT01844583 Phase I Alisertib + Esomeprazole Alisertib + Rifampin Alisertib Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib Completed
NCT01877382 Phase I DS-3032b A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Recruiting
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Active, not recruiting
NCT01897012 Phase I romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed
NCT01898078 Phase I Alisertib Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas Unknown status
NCT01905228 Phase I CBL0137 A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas Recruiting
NCT01908413 Phase I GDC-0917 Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Terminated
NCT01943682 Phase I CPX-351 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Active, not recruiting
NCT01991938 Phase I VS-5584 Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Terminated
NCT01992653 Phase I Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab Vedotin Obinutuzumab A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Completed
NCT02042989 Phase I Ixazomib + Vorinostat MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies Active, not recruiting
NCT02216409 Phase I Hu5F9-G4 Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody Completed
NCT02249429 Phase Ib/II PQR309 Open-Label, Non Randomized Phase 2 Study With Safety Run-In Completed
NCT02259010 Phase I Alisertib Itraconazole A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma Unknown status
NCT02309580 Phase I Ibrutinib Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma Recruiting
NCT02318329 Phase I FPA144 Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02323880 Phase I Selinexor Study of Selinexor in Pediatric Solid Tumors Recruiting
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting
NCT02337985 Phase I Rituximab Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Filgrastim Prednisone Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
NCT02343718 Phase I Temsirolimus + Vinblastine Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Completed
NCT02355535 Phase I PAC-1 Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies Recruiting
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Sirolimus + Tacrolimus + Methotrexate Doxorubicin + Etoposide + Fludarabine + Vincristine Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Active, not recruiting
NCT02392611 Phase I GS-5829 + Exemestane Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas Completed
NCT02414724 Phase I Gemcitabine + Ribociclib Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma Terminated
NCT02431260 Phase I INCB054329 An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies Completed
NCT02432235 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Recruiting
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02465060 Phase II Dabrafenib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Binimetinib Adavosertib Osimertinib Trastuzumab Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib trastuzumab emtansine Larotrectinib Pertuzumab Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting
NCT02499861 Phase Ib/II Genistein + Decitabine Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies Completed
NCT02503423 Phase Ib/II ASTX-660 Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Recruiting
NCT02516813 Phase I MSC2490484A Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Recruiting
NCT02518113 Phase Ib/II Dexamethasone LY3039478 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Completed
NCT02518750 Phase II Panobinostat + Bortezomib + Dexamethasone Pegaspargase Mercaptopurine Nelarabine Mitoxantrone Vincristine Cyclophosphamide + Etoposide Cytarabine + Methotrexate + Prednisone Clofarabine Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated
NCT02518958 Phase I Nivolumab A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab Active, not recruiting
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn
NCT02552953 Phase I CYC065 A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers Recruiting
NCT02582827 Phase I ABI-011 QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas Recruiting
NCT02624388 Phase II Genistein Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting
NCT02663518 Phase I TTI-621 A Trial of TTI-621 for Patients With Hematologic Malignancies Recruiting
NCT02675439 Phase I Ipilimumab + MIW815 MIW815 Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas Recruiting
NCT02681302 Phase Ib/II Nivolumab + Ipilimumab Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001) Recruiting
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated
NCT02694822 Phase I AGEN1884 AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers Recruiting
NCT02729896 Phase Ib/II Atezolizumab + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02740270 Phase I GWN 323 + PDR001 GWN 323 Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas Active, not recruiting
NCT02780011 Phase I Alisertib + Brentuximab vedotin Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies Withdrawn
NCT02780804 Phase I Entinostat Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting
NCT02783625 Phase I Bortezomib + Duvelisib Duvelisib + romidepsin Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas Recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3039478 + LY3023414 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02786485 Phase I Rimiducid BPX-501 Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn
NCT02793466 Phase I Durvalumab Durvalumab in Pediatric and Adolescent Patients Recruiting
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Recruiting
NCT02812875 Phase I CA-170 A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas Recruiting
NCT02846935 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Completed
NCT02875548 Phase II Tazemetostat Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study Recruiting
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Recruiting
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02932280 Phase Ib/II Neratinib Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Recruiting
NCT02935907 Phase I APG-115 APG-115 in Patients With Advanced Solid Tumors or Lymphomas Recruiting
NCT02992483 Phase I MIK665 Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma Recruiting
NCT03005782 Phase I REGN3767 + REGN2810 REGN3767 Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Recruiting
NCT03010176 Phase I MK-1454 + Pembrolizumab MK-1454 Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Recruiting
NCT03011372 Phase II Pemigatinib A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement Recruiting
NCT03013218 Phase I ALX148 ALX148 + Atezolizumab ALX148 + Trastuzumab A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma Recruiting
NCT03013491 Phase II CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072 A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas Recruiting
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Suspended
NCT03030417 Phase I LMP744 Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas Suspended
NCT03061188 Phase I Veliparib + Nivolumab Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes Recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Olaparib Selumetinib Ensartinib Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas Recruiting
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03172936 Phase I MIW815 + PDR001 Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas Recruiting
NCT03192202 Phase Ib/II AFM13 AFM13 in Relapsed/Refractory Cutaneous Lymphomas Recruiting
NCT03194893 Phase III Crizotinib Alectinib A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03205176 Phase I AZD5153 Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas Recruiting
NCT03229200 FDA approved Ibrutinib Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation
NCT03229278 Phase I Nivolumab + Pembrolizumab + Trigriluzole Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Recruiting
NCT03249792 Phase I MK-2118 + Pembrolizumab MK-2118 Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001) Recruiting
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT03291938 Phase I IACS-010759 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma Recruiting
NCT03309878 Phase Ib/II Pembrolizumab Mogamulizumab + Pembrolizumab Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas Recruiting
NCT03311412 Phase I Sym021 Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Recruiting
NCT03316573 Phase II Pembrolizumab A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting
NCT03322384 Phase Ib/II Epacadostat + SD-101 Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Recruiting
NCT03323034 Phase I Irinotecan + MLN4924 + Temozolomide Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Recruiting
NCT03323398 Phase I mRNA-2416 Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies Recruiting
NCT03332355 Phase I PAC-1 + Temozolomide Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 Recruiting
NCT03359733 Phase I TAK-659 A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor Withdrawn
NCT03365791 Phase II LAG525 PDR001 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03418038 Phase II Dexamethasone Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Rituximab Cytarabine + Dexamethasone + Oxaliplatin Gemcitabine + Oxaliplatin Cisplatin + Cytarabine + Dexamethasone + Rituximab Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma Recruiting
NCT03435250 Phase I AG-270 Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss Recruiting
NCT03445858 Phase I Pembrolizumab + Decitabine Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Recruiting
NCT03451825 Phase Ib/II Avelumab Phase I/II Study of Avelumab in Pediatric Cancer Subjects Recruiting
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Not yet recruiting
NCT03489343 Phase I Sym023 Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Recruiting
NCT03489369 Phase I Sym022 Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Recruiting
NCT03502733 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma Recruiting
NCT03530683 Phase I TTI-622 A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma Recruiting
NCT03654716 Phase I ALRN-6924 + Cytarabine Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03739931 Phase I mRNA-2752 mRNA-2752 + Tremelimumab Duvalumab + mRNA-2752 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies Recruiting
NCT03763149 Phase I IBI188 A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas Recruiting
NCT03841110 Phase I FT500 + Pembrolizumab Atezolizumab + FT500 FT500 + Nivolumab FT500 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors Not yet recruiting